Elotuzumab for the treatment of multiple myeloma
- PMID: 24941981
- DOI: 10.2217/fon.14.56
Elotuzumab for the treatment of multiple myeloma
Abstract
New agents are awaited for the treatment of multiple myeloma and research is ongoing for the development of monoclonal antibodies (MoAbs) targeting the tumor cells. One of the most promising MoAb is elotuzumab, the only humanized IgG1 MoAb specifically targeting CS1 (SLAMF7), a cell surface glycoprotein that is highly expressed in plasma cells. Preclinical and clinical data on elotuzumab will be presented in this article.
Keywords: CS1; elotuzumab; lenalidomide; monoclonal antibody; multiple myeloma.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous